Flash FinanceUS
Market closed S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Charles River Laboratories (CRL)

Charles River Q3 revenue falls 1.6% to $1.01 billion; raises non-GAAP EPS outlook

Mixed Impact 4 of 5 guidance Written later

Charles River reported third-quarter 2024 revenue of $1.01 billion, down 1.6% from a year earlier, with GAAP diluted EPS of $1.33, down 21.3%, and non-GAAP diluted EPS of $2.59, down 4.8%. The company raised its 2024 non-GAAP EPS guidance to $10.10-$10.30 from $9.90-$10.20 but cut its GAAP EPS guidance to $5.30-$5.50 from $5.65-$5.95, citing higher restructuring charges.

Key points

  • Q3 revenue $1.01 billion vs. $1.03 billion in Q3 2023; organic revenue declined 2.7%
  • GAAP diluted EPS $1.33 vs. $1.69; non-GAAP diluted EPS $2.59 vs. $2.72
  • 2024 non-GAAP EPS guidance raised to $10.10-$10.30; GAAP EPS guidance cut to $5.30-$5.50
  • Board approved a $1.0 billion buyback on August 2, 2024; $899.3 million remained as of September 28, 2024

The filing

CompanyCharles River Laboratories (CRL)
Form8-K, current report
Filed with the SECNov 6, 2024, 7:21 AM ET
Accession number0001100682-24-000033

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 1:11 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on November 06, 2024.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.